Whether a commercial plan pays for Mounjaro turns almost entirely on one question, and it is not a question about the drug's price. It is what the prescription says the drug is for. The label decides what a plan is being asked to cover, and what the maker’s card is allowed to help with.
The label covers diabetes, and only diabetes
Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults and in patients aged 10 and over with type 2 diabetes[1]. It is also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for them[1].
There is no weight indication on that list. Tirzepatide is approved for weight under a different brand name, which is why a plan can cover one and exclude the other; the two are compared in Mounjaro vs Zepbound.
Dosing shapes the bill as well. Treatment starts at 2.5 mg once weekly and may rise in 2.5 mg steps after at least four weeks on a dose, to an adult maximum of 15 mg[1].
What employer plans are actually doing
The 2025 employer health benefits survey, which interviewed 1,862 firms, reports that health plans have generally covered these medications when they are prescribed for people with diabetes[2].
Coverage for weight loss is a different picture, and it rises steeply with the size of the employer. Among firms with 200 or more workers that offer benefits, 16% of those with 200 to 999 workers cover GLP-1s when used primarily for weight loss[2]. That reaches 30% at firms with 1,000 to 4,999 workers and 43% at firms with 5,000 or more[2].
Overall, 19% of firms with 200 or more workers cover them for weight loss, close to the 18% recorded a year earlier[2]. Of the firms that do, 34% require the enrollee to meet a dietitian, case manager or therapist, or to join a lifestyle program[2].
What the card is worth, and where it stops
| Your situation | What the card does | Its ceiling |
|---|---|---|
| Commercial plan that covers Mounjaro | Pay as little as $25 per fill | $150 a month, $1,950 a year |
| Commercial plan that does not cover it | Pay as low as $499 a month | $647 a month, $8,411 a year |
| Any government program | Not eligible | No card at all |
| No insurance | Not eligible for the card | Self-pay is $499 a month |
Both tiers run through the same program, and both expire on December 31, 2026[3]. The covered tier is capped at $150 on a one-month fill, rising to $450 on a three-month one, a spread of $300[3].
The card also carries a clause worth reading before enrolling. If a plan uses an alternate funding program that requires enrollment in the card as a condition of coverage, the patient is prohibited from using the card at all[3].
And the card never applies to anyone in a state, federal or government-funded program, including Medicaid, Medicare, Medicare Advantage, Medigap, the Department of Defense, the VA and TRICARE[3]. Those routes are covered in does Medicare cover Mounjaro and does Medicaid cover Mounjaro.
If the plan says no
Lilly’s own pharmacy service prices the single-dose pen at $499 a month at every dose from 2.5 mg to 15 mg, with taxes and fees on top[4].
That figure is the practical ceiling on the brand, and it is what the full price comparison in Mounjaro cost is built around. The compounded tirzepatide market is a separate question with separate rules, priced on the tirzepatide price board.
Whichever route applies, the number that matters is the one after fees. The all-in monthly calculator folds a consult, a membership and shipping into any quote.
Four questions for the plan, in order
- Is Mounjaro on the formulary, and at which tier?
- Does it need prior authorization, and what diagnosis codes satisfy it?
- Is step therapy required, and which drugs have to fail first?
- Does the plan use an alternate funding vendor for specialty drugs?
The last one changes the answer to everything above, because it decides whether the manufacturer card is usable at all.